Vauthey J N, Marsh R de W, Cendan J C, Chu N M, Copeland E M
Department of Surgery, College of Medicine, University of Florida, Gainesville 32610-0286, USA.
Br J Surg. 1996 Apr;83(4):447-55. doi: 10.1002/bjs.1800830405.
Considerable experience of the treatment of irresectable hepatic colorectal metastases has accumulated over the past three decades. In this review, the rationale for hepatic artery treatment of colorectal metastases to the liver is presented and various access techniques and chemotherapeutic agents for infusion are discussed. Randomized trials of hepatic artery chemotherapy (HAC) are analysed, and the promising results of recent studies combining less toxic and more effective agents are summarized. Continuous infusion pumps provide the most reliable and long-lasting access for HAC. Appropriate surgical techniques and medical management can minimize complications. Although tumour progression is best controlled by HAC, a clear-cut survival advantage has yet to be demonstrated. While hepatic artery infusion chemotherapy cannot yet be recommended outside investigational protocols, the experience gained so far should stimulate further studies.
在过去三十年中,积累了大量关于不可切除性肝结直肠癌转移瘤治疗的经验。在这篇综述中,阐述了对肝内结直肠癌转移灶进行肝动脉治疗的基本原理,并讨论了各种介入技术和用于灌注的化疗药物。分析了肝动脉化疗(HAC)的随机试验,并总结了近期联合使用毒性较小且更有效的药物的研究的有前景的结果。持续输注泵为HAC提供了最可靠且持久的通路。适当的手术技术和医疗管理可将并发症降至最低。尽管HAC能最好地控制肿瘤进展,但尚未证明其具有明确的生存优势。虽然目前在研究方案之外尚不能推荐肝动脉灌注化疗,但迄今获得的经验应能刺激进一步的研究。